Outpatient Prescription Opioid Use following Discharge after Deep Inferior Epigastric Perforator Breast Reconstruction with and without an Educational Intervention

Abstract

Background There is limited evidence for appropriate postoperative opioid prescribing in autologous breast reconstruction. We sought to describe postoperative outpatient prescription opioid use following discharge after deep inferior epigastric perforator (DIEP) breast reconstruction with and without an educational video.

Methods Patients undergoing DIEP reconstruction were given a 28-day postoperative pain and medication logbook from August 2022 to June 2023. Our practice implemented an educational video upon discharge on proper opioid consumption. Descriptive statistics on patient characteristics, intraoperative and postoperative opioid consumption, and outpatient prescription opioid use after discharge were compared between the two cohorts.

Results A total of 53 logbooks were completed with 20 patients in the no video cohort and 33 in the video cohort. On average, the days to cessation of opiates was longer in the no video cohort (8.2 vs. 5.1 days, p = 0.003). The average number of oxycodone 5 mg equivalents consumed following discharge was 13.8 in the no video cohort and 7.8 in the video cohort, which was statistically significant (p = 0.01). Overall, the percentage of opioids prescribed that were consumed in the video cohort was 28.3% versus 67.1% in the no video cohort.

Conclusion For patients discharging home after DIEP reconstruction, we recommend a prescription for 12 oxycodone 5 mg tablets. With the use of an educational video regarding proper opioid consumption, we were able to reduce the total outpatient opioid use to 5 oxycodone 5 mg tablets following hospital discharge.

Keywords

opioid prescribing guidelines - breast reconstruction - postoperative opioids - postoperative pain control

Author Contributions

All authors above appropriately contributed to the development of this manuscript. The conceptualization of the goals/aims of the article were driven by J.P.A. and A.C.K. The formal acquisition of the data was carried out by J.L.M., J.C., W.M., and J.L. Data analysis was conducted by D.E. J.M., J.C., W.M., J.P.A., and A.C.K. were involved in drafting and revising the final version for submission.

Publikationsverlauf

Eingereicht: 23. Dezember 2023

Angenommen: 20. Februar 2024

Accepted Manuscript online:
07. März 2024

Artikel online veröffentlicht:
26. März 2024

• References

• 1 Trakimas DR, Perez-Heydrich C, Mandal R. et al. Peri-operative pain and opioid use in opioid-naïve patients following inpatient head and neck surgery. Front Psychiatry 2022; 13: 857083
• 2 Upp LA, Waljee JF. The opioid epidemic. Clin Plast Surg 2020; 47 (02) 181-190
• 3 Buffington DE, Lozicki A, Alfieri T, Bond TC. Understanding factors that contribute to the disposal of unused opioid medication. J Pain Res 2019; 12: 725-732
• 4 Hill MV, McMahon ML, Stucke RS, Barth Jr RJ. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg 2017; 265 (04) 709-714
• 5 Understanding the epidemic. Centers for Disease Control and Prevention. Accessed October 18, 2023 at: https://www.cdc.gov/drugoverdose/epidemic/index.html
• 6 Howard R, Fry B, Gunaseelan V. et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg 2019; 154 (01) e184234
• 7 Hart AM, Broecker JS, Kao L, Losken A. Opioid use following outpatient breast surgery: are physicians part of the problem?. Plast Reconstr Surg 2018; 142 (03) 611-620
• 8 Prescribing recommendations opioid prescribing engagement network. Accessed September 18, 2023 at: https://michagan-open.org/prescribing-recommendations/updated
• 9 Haddock NT, Garza R, Boyle CE, Liu Y, Teotia SS. Defining enhanced recovery pathway with or without liposomal bupivacaine in DIEP flap breast reconstruction. Plast Reconstr Surg 2021; 148 (05) 948-957
• 10 Van Boerum MS, Mann SL, Veith JP. et al. Patient-reported opioid use for tissue expander-based breast reconstruction. J Plast Reconstr Aesthet Surg 2021; 74 (11) 2899-2905
• 11 Huynh V, Rojas K, Ahrendt G. et al. Reassessing opioid use in breast surgery. J Surg Res 2020; 254: 232-241
• 12 Kroll SS, Sharma S, Koutz C. et al; Evans GRD. Postoperative morphine requirements of free TRAM and DIEP flaps. Plast Reconstr Surg 2001; 107 (02) 338-341
• 13 Calculating total daily dose of opioids for safer dosage. U.S. Department of Health and Human Services. Accessed August 21, 2023 at: https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf
• 14 Cheah MA, Sarmiento S, Lesko RP. et al. Association of preoperative opioid use and postoperative complications following breast reconstruction. J Plast Reconstr Aesthet Surg 2023; 83: 258-265
• 15 Johnson AC, Colakoglu S, Reddy A. et al. Perioperative blocks for decreasing postoperative narcotics in breast reconstruction. Anesth Pain Med 2020; 10 (05) e105686
• 16 Persing S, Manahan M, Rosson G. Enhanced recovery after surgery pathways in breast reconstruction. Clin Plast Surg 2020; 47 (02) 221-243
• 17 Momeni A, Ramesh NK, Wan D, Nguyen D, Sorice SC. Postoperative analgesia after microsurgical breast reconstruction using liposomal bupivacaine (Exparel). Breast J 2019; 25 (05) 903-907
• 18 Offodile II AC, Gu C, Boukovalas S. et al. Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2019; 173 (01) 65-77
• 19 Chattopadhyay A, Shah JK, Yesantharao P, Ho VT, Sheckter CC, Nazerali R. Transversus abdominus plane blocks do not reduce rates of postoperative prolonged opioid use following abdominally based autologous breast reconstruction: a nationwide longitudinal analysis. Eur J Plast Surg 2023; 46 (02) 203-213
• 20 Lu YH, Jeon J, Mahajan L, Yan Y, Weichman KE, Ricci JA. Postoperative magnesium sulfate repletion decreases narcotic use in abdominal-based free flap breast reconstruction. J Reconstr Microsurg 2024; 40 (07) 559-565
• 21 Fearon NJ, Kurtzman J, Benfante N. et al. Reducing opioid prescribing after ambulatory breast reconstruction surgery. J Surg Oncol 2023; 128 (08) 1235-1242
• 22 Rodnoi P, Dickey RM, Teotia SS, Haddock NT. Increased opioid consumption following DIEP flap breast reconstruction: effect of depression and anxiety. J Reconstr Microsurg 2022; 38 (09) 742-748
• 23 Nelson JA, Polanco TO, Shamsunder MG. et al. Perioperative inpatient opioid consumption following autologous free-flap breast reconstruction patients: an examination of risk and patient-reported outcomes. Ann Surg Oncol 2021; 28 (12) 7823-7833
• 24 Egan KG, De Souza M, Muenks E, Nazir N, Korentager R. Predictors of opioid consumption in immediate, implant-based breast reconstruction. Plast Reconstr Surg 2020; 146 (04) 734-741
• 25 Egan KG, De Souza M, Muenks E, Nazir N, Korentager R. Opioid consumption following breast surgery decreases with a brief educational intervention: a randomized, controlled trial. Ann Surg Oncol 2020; 27 (09) 3156-3162
• 26 Sudduth JD, Moss WD, Clinker C. et al. Scheduled postoperative ketorolac does not decrease opiate use following free flap breast reconstruction. J Reconstr Microsurg 2023; 39 (09) 751-757
• 27 Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005; 330 (7493) 702
• 28 Stark N, Kerr S, Stevens J. Prevalence and predictors of persistent post-surgical opioid use: a prospective observational cohort study. Anaesth Intensive Care 2017; 45 (06) 700-706
• 29 McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67 (03) 267-277